Results of an investigation have revealed the connection between immunotherapy and decrease in artery plaque in Psorasis patients. The results were printed in the periodical, ‘Cardiovascular Research’.
The investigation involved analysis of biologic drugs used as an immunosuppressant in Psorasis patients and its effectiveness in reducing artery plaque. The investigating team headed by Dr. Mehta, who is an expert into Cardiometabolic and Inflammation related Diseases, used available data from National Institutes of Health Psorasis Atherosclerosis Cardiometabolic Initiative cohort. Out of 290 patients under observation, 121 participants were picked up with moderate to severe grades of the disease and put them on biologic drugs. A clinical observation for a year followed after which the group’s artery health was compared with the group who were not under the biologic medication. The assessments were done through coronary computed tomography angiography. The group on biologic drugs exhibited an 8% reduction of plaque on the coronary artery. Plaque buildup over a period causes strokes or heart attacks.
However, certain intriguing findings were revealed by the study. One was the change in the coronary plaque sub-constituents over a single year including the non-calcified and necrotic core constituents which are main reasons for a heart attack. The researchers felt that an anti-inflammatory effect was under play as with no change in medications or enhancement of other related risk causes the soft-plaque showed signs of improvement. The skin disease’s severity though had changed.
The researchers remarked that inflammation was an additional factor besides the regular five factors of hypertension, diabetes, high cholesterol, smoking and family history for being the causes of heart attacks. Inflammation definitely affected the development and advancement of atherosclerosis to a stroke.
The researchers further remarked that more study was needed in this context. Further to their observational study there was a need for conducting randomized controlled trials.
With a master’s degree in medical science, Michael is committed to completing case studies on the development and procedures of new medical devices. It contains a vast knowledge base of medical science and technology that clarifies certain key sectors such as surgical devices for the supply and diagnosis of medications. He is naturally experienced and is known for explaining things in a decent way. He is accustomed to riding a bicycle and is a coffee lover.